TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22560756

Group type: EXPERIMENTAL
Intervention: 10 minutes tactile
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20 minutes tactile
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 minutes nontactile
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20 minutes nontactile
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (neutral reading)
Number of subjects: 20
Study: 20232605

Group type: EXPERIMENTAL
Intervention: Telephone counseling along with a home telemonitoring scale and instructions to self‐weigh daily
Number of subjects: 100
Study: 18412682

Group type: EXPERIMENTAL
Intervention: Residential mobility rate
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Socio-demographic factors
Number of subjects: 585
Study: 15998777

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (0.5 g, then 0.25 g, 6 wk each)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral prednisolone starting with 0.1 g/d, then tapering the dose by 0.01 g/wk
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoid therapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intravenous steroids
Number of subjects: 70
Study: 12776578

Group type: EXPERIMENTAL
Intervention: Ebastine (10 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fexofenadine (60 mg, twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg once daily)
Number of subjects: 0
Study: 10323778

Group type: EXPERIMENTAL
Intervention: High plasma tHcy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lowest tHcy quintile
Number of subjects: 100
Study: 8603453

Group type: EXPERIMENTAL
Intervention: ThioTEPA 30 mg/30 ml distilled water
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ThioTEPA 30 mg/60 ml distilled water
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ThioTEPA 60 mg/30 ml distilled water
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ThioTEPA 60 mg/60 ml distilled water
Number of subjects: 8
Study: 2177347

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 142

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 142
Study: 54579

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (5000 units of sodium heparin every 12 hours for 5 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no heparin treatment)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-dose heparin treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 31493728

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) anticoagulants (Vitamin K antagonists or Low Molecular Weight Heparin)
Number of subjects: 0
Study: 28445291

Group type: EXPERIMENTAL
Intervention: Propofol/sevoflurane anesthesia (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol-based TIVA (n=25)
Number of subjects: 50
Study: 25377272

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (CNI, MMF, corticosteroids)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: CNI therapy after belatacept withdrawal
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: MMF monotherapy after belatacept withdrawal
Number of subjects: 4
Study: 23646319

Group type: EXPERIMENTAL
Intervention: Hybrid MSI
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cylindric MSI
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both MSIs
Number of subjects: 10
Study: 21432821

Group type: EXPERIMENTAL
Intervention: Global longitudinal strain (GLS) analysis in patients with AS
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: GLS in hypertrophy Groups 3 and 4
Number of subjects: 44
Study: 19196206

Group type: EXPERIMENTAL
Intervention: Immediate cord clamping (ICC) at 5-10 seconds
Number of subjects: 65

Group type: COMPARATOR
Intervention: Delayed cord clamping (DCC) at 30-45 seconds
Number of subjects: 65
Study: 21736507

Group type: EXPERIMENTAL
Intervention: Sequential bilateral rTMS
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Unilateral rTMS
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 74
Study: 15585750

Group type: EXPERIMENTAL
Intervention: Dialogic reading
Number of subjects: 28

Group type: COMPARATOR
Intervention: Typical reading
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 12897740

Group type: EXPERIMENTAL
Intervention: Intervention (occupant education, insecticide bait placement, professional cleaning)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 31
Study: 9460945

Group type: EXPERIMENTAL
Intervention: Triosite blocks
Number of subjects: 341

Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 341
Study: 7639229

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate with food
Number of subjects: 41

Group type: COMPARATOR
Intervention: Ranitidine bismuth citrate without food
Number of subjects: 41
Study: 2526419

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (standard doses)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (third dose late, >7 months after first dose)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Various schedules of dose timing (early/late second and third doses)
Number of subjects: 373
Study: 331502

Group type: EXPERIMENTAL
Intervention: Bumadizone calcium
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 56
Study: 11952465

Group type: COMPARATOR
Intervention: 50 microgs of oral misoprostol, repeated every 4 h to a maximum of 5 doses.
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 100 microgs of oral misoprostol, repeated every 4 h to a maximum of 5 doses.
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Patient satisfaction assessed by postnatal questionnaire.
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Preference for oral inducing agent if another induction is needed.
Number of subjects: 251
Study: 29457873

Group type: EXPERIMENTAL
Intervention: Video endoscopic examination (VEE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard endoscopic examination (SEE)
Number of subjects: 0
Study: 27568303

Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 24807325

Group type: EXPERIMENTAL
Intervention: Suture closure
Number of subjects: 746

Group type: COMPARATOR
Intervention: Staple closure
Number of subjects: 746
Study: 23717118

Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG) in CT genotype of G protein beta 3 gene
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG) in Trp64/Arg genotype of beta 3 adrenergic receptor gene
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG) in DD genotype of angiotensin I converting enzyme gene
Number of subjects: 50
Study: 20056980

Group type: EXPERIMENTAL
Intervention: Triple incision method group (TIMG)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Swan neck catheter group (SNCG)
Number of subjects: 101
Study: 18539195

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey formula
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey formula
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula
Number of subjects: 2252

Group type: COMPARATOR
Intervention: Cow's milk formula (CMF)
Number of subjects: 2252
Study: 16167646

Group type: EXPERIMENTAL
Intervention: International accreditation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Before trial
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: After trial
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Accredited units
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Non-accredited units
Number of subjects: 51
Study: 12010707

Group type: EXPERIMENTAL
Intervention: Computer-based instruction (n = 29)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Traditional lecture-based instruction (n = 32)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combined computer-based and lecture-based instruction (n = 33)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combined group (n = 33)
Number of subjects: 94
Study: 10452771

Group type: EXPERIMENTAL
Intervention: Cow's milk formula (1789 infants)
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Pasteurized human milk (1859 infants)
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula (1737 infants)
Number of subjects: 6209

Group type: COMPARATOR
Intervention: Exclusive breast-feeding (824 infants)
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Exposure to CM while in the hospital
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Obvious parental atopy
Number of subjects: 6209
Study: 7885287

Group type: EXPERIMENTAL
Intervention: Brisk walking (average of 21 +/- 1 min.d-1 at 1.76 +/- 0.02 m.s-1)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (maintained habitual lifestyle)
Number of subjects: 26
Study: 2203140

Group type: EXPERIMENTAL
Intervention: Multimodal tumor therapy
Number of subjects: 0
Study: 364910

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day) for 28 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day)
Number of subjects: 39
Study: 31026303

Group type: EXPERIMENTAL
Intervention: CVVHD using regional citrate anticoagulation and a high-cut-off dialyzer
Number of subjects: 60

Group type: COMPARATOR
Intervention: CVVHD using regional citrate anticoagulation and a high-flux dialyzer
Number of subjects: 60
Study: 28582393

Group type: EXPERIMENTAL
Intervention: Framingham equation with BMI
Number of subjects: 2056

Group type: EXPERIMENTAL
Intervention: Framingham equation with lipids
Number of subjects: 2056

Group type: COMPARATOR
Intervention: Early ART
Number of subjects: 2056
Study: 25240168

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) imaging pre- and post-stent implantation
Number of subjects: 29
Study: 23575913

Group type: EXPERIMENTAL
Intervention: Relative phase feedback training
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Speed feedback training
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Grip force feedback training
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Video feedback training
Number of subjects: 22
Study: 21625183

Group type: EXPERIMENTAL
Intervention: Trastuzumab treatment continued after diagnosis of BM
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Surgery and radiotherapy for BM
Number of subjects: 75

Group type: COMPARATOR
Intervention: First-line chemotherapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Overall survival (OS) after diagnosis of MBC
Number of subjects: 75
Study: 19927726

Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil anaesthesia (Group PR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane and remifentanil anaesthesia (Group S)
Number of subjects: 40
Study: 16703336

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative alone (group 1, n=10)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination of enamel matrix derivative and bioactive glass (group 2, n=13)
Number of subjects: 23
Study: 12658483

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) 0.3 IU/kg/day subcutaneously from day 3 before operation until day 7 after operation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) and Placebo
Number of subjects: 20
Study: 10955339

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) for RA
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) for OA
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo laser for RA
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control group using opposite hand for RA
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo laser for OA
Number of subjects: 409
Study: 8820685

Group type: EXPERIMENTAL
Intervention: Biosporin (2 x 10^9 microbial cells of Bacillus subtilis and Bacillus licheniformis)
Number of subjects: 0
Study: 1431344

Group type: EXPERIMENTAL
Intervention: Anti-CEA monoclonal antibody (F023C5) radioimmunoscintigraphy (RIS)
Number of subjects: 509

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 509

Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 509

Group type: COMPARATOR
Intervention: US
Number of subjects: 509
Study: 3855601

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 in 1 mg dose
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 in 2 mg dose
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 in 3 mg dose
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (vaginal triacetin gel)
Number of subjects: 80
Study: 30794143

Group type: EXPERIMENTAL
Intervention: Dedicated mobility technician-assisted ambulation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 102
Study: 29663984

Group type: EXPERIMENTAL
Intervention: STEP (intervention group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: CON (control group)
Number of subjects: 120
Study: 26997458

Group type: EXPERIMENTAL
Intervention: URSA-S
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 24603216

Group type: EXPERIMENTAL
Intervention: Low activation music (LA/PV and LA/NV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: High activation/negative valence music (HA/NV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no music)
Number of subjects: 100
Study: 22045925

Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM) for 6 months, measuring body weight, blood pressure, and heart rate daily with electronic devices.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care (UC) for 6 months.
Number of subjects: 160
Study: 20101186

Group type: EXPERIMENTAL
Intervention: Valproate (20 mg/kg/day)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Lithium (800 mg/day)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 268

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 268
Study: 18037769

Group type: EXPERIMENTAL
Intervention: Pycnogenol (180 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 16287384

Group type: EXPERIMENTAL
Intervention: Culturally adapted Parent Management Training intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 12099651

Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy
Number of subjects: 615
Study: 10392392

Group type: EXPERIMENTAL
Intervention: 1450 T lead (steroid group)
Number of subjects: 95

Group type: COMPARATOR
Intervention: 1451 T lead (nonsteroid group)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both leads (1450 T and 1451 T)
Number of subjects: 95
Study: 8728171

Group type: EXPERIMENTAL
Intervention: Intraperitoneal minoxidil
Number of subjects: 21

Group type: COMPARATOR
Intervention: Minoxidil-free cycles
Number of subjects: 21
Study: 1824736

Group type: EXPERIMENTAL
Intervention: mannitol (15‐g bolus followed by 15% infusion mixed in 75 mmol/L saline at 100 mL/h for 1 hour)
Number of subjects: 20

Group type: COMPARATOR
Intervention: saline (equal volume of 75 mmol/L saline, intravenously)
Number of subjects: 20
Study: 6341653

Group type: EXPERIMENTAL
Intervention: Cefamandole (CMD)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Cefmetazole (CMZ)
Number of subjects: 193
Study: 31345387

Group type: EXPERIMENTAL
Intervention: reduced-dose chemoradiation (rdCRT) with 5600 cGy and weekly carboplatin
Number of subjects: 23

Group type: COMPARATOR
Intervention: standard-dose chemoradiotherapy (sdCRT) with 7000 cGy
Number of subjects: 23
Study: 28416009

Group type: EXPERIMENTAL
Intervention: Community Health Workers (CHWs) conducting household visits using Lot Quality Assurance Sampling (LQAS) methodology.
Number of subjects: 4616

Group type: COMPARATOR
Intervention: Community Health Workers (CHWs) in Luangwa high school.
Number of subjects: 4616

Group type: COMPARATOR
Intervention: Community Health Workers (CHWs) in other teams.
Number of subjects: 4616
Study: 26228291

Group type: COMPARATOR
Intervention: 0.5 mg ranibizumab (RBZ)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab (RBZ)
Number of subjects: 152
Study: 24072232

Group type: EXPERIMENTAL
Intervention: Everolimus-Continuation
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Everolimus Responders
Number of subjects: 89
Study: 21914410

Group type: EXPERIMENTAL
Intervention: Intrathecal immunoglobulin in addition to standard treatment (group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard treatment only (group B)
Number of subjects: 70
Study: 18312768

Group type: COMPARATOR
Intervention: Combined simvastatin and ezetimibe treatment
Number of subjects: 1720
Study: 16842145

Group type: EXPERIMENTAL
Intervention: New pharmacological approaches to improve vascular homeostasis, specifically targeting oxidative stress reduction or antioxidant defense augmentation.
Number of subjects: 0
Study: 15160263

Group type: EXPERIMENTAL
Intervention: Perospirone 4 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg plus perospirone 4 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paroxetine 20 mg
Number of subjects: 20
Study: 10831905

Group type: EXPERIMENTAL
Intervention: Preservative-free 1% lignocaine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 68
Study: 9369917

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for chemo-sensitive tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water-sealed tube drainage and pleurodesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Talc slurry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pericardiocentesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instillation of drugs like doxycycline, OK-432, or bleomycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thoraco-abdominal shunting and pleuro-pneumonectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous continuous drainage, pericardial fenestration, or pericardio-thoraco fenestration
Number of subjects: 0
Study: 8419600

Group type: EXPERIMENTAL
Intervention: Helium-oxygen mixture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrogen-oxygen mixture
Number of subjects: 0
Study: 3512070

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy plus immunotherapy with Nocardia rubra cell-wall skeleton (N-CWS) and irradiated allogeneic AML cells
Number of subjects: 73

Group type: COMPARATOR
Intervention: Maintenance chemotherapy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy group
Number of subjects: 73
Study: 2456566

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30524633

Group type: EXPERIMENTAL
Intervention: Combination Therapy (CT) with lumbopelvic stability training (LPST)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard Massage Therapy (MT)
Number of subjects: 16
Study: 28324268

Group type: EXPERIMENTAL
Intervention: Ridaforolimus 30 mg daily for 5 of 7 days plus dalotuzumab 10 mg/kg/week
Number of subjects: 62

Group type: COMPARATOR
Intervention: Exemestane 25 mg/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Any ridaforolimus dose
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ridaforolimus 20 mg qd x 5 days/week
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ridaforolimus 10 mg qd x 5 days/week
Number of subjects: 62
Study: 25713953

Group type: EXPERIMENTAL
Intervention: 60-minute, theory-based, safer sex intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Didactic time-equivalent attention control
Number of subjects: 400
Study: 23833847

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Saline)
Number of subjects: 60
Study: 20462580

Group type: EXPERIMENTAL
Intervention: Home-based deep-breathing training
Number of subjects: 62

Group type: COMPARATOR
Intervention: Weekly telephone support
Number of subjects: 62
Study: 18250500

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Conventional methods of care (CMC)
Number of subjects: 206
Study: 16299259

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO(2)) at 2.0 ATA for 2 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO(2)) over 20 treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO(2))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO(2)) in mice
Number of subjects: 0
Study: 15270890

Group type: EXPERIMENTAL
Intervention: Topical paricalcitol ointment (15 microg g(‐1))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 11
Study: 12067146

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2T)
Number of subjects: 42
Study: 9359979

Group type: EXPERIMENTAL
Intervention: moclobemide (MOC; 400 mg daily)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: nortriptyline (NT; 75 mg daily)
Number of subjects: 95

Group type: COMPARATOR
Intervention: placebo (PBO)
Number of subjects: 95
Study: 8335816

Group type: EXPERIMENTAL
Intervention: Regular physical exercise (mean energy expended: 1,876 ± 163 kcal/week)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care (mean energy expended: 1,187 ± 97 kcal/week)
Number of subjects: 62